- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02810249
Likely Use of PrEP for African American YMSM
Factors Affecting the Likely Use of PrEP for African American Young Men Who Have Sex With Men
Study Overview
Detailed Description
This study will use an exploratory, naturalistic qualitative design where participants will be interviewed to collect data on their emotional and cognitive processes (illness representation) in response to the threat of a potential HIV infection, and what factors (social, cultural, individual characteristics, and experiences in health care) influence their likely use of PrEP. The sample for this study will include 20 to 30 African American YMSM, aged 16-24, residing in Durham, Wake, and Orange counties of North Carolina.
The in-depth interview guide and the 26-item descriptive survey PrEP Knowledge, Sexual History, and Demographic Instrument were developed for this study using a combination of the concepts from the adapted Common Sense Model of Illness Representation (CSM) and questions adapted from the Adolescent Trial Network's (ATN) 082 study's questionnaire. Participants will be asked questions relating to African American YMSM's likely use of HIV Pre-Exposure Prophylaxis (PrEP) as an HIV risk-reduction strategy. Once informed consent is obtained, the interview will commence and study participants will be individually interviewed to discuss what factors influence their likely use of PrEP. Each participant will complete the descriptive survey and the one-on-one interview.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- between the ages of 16-24
- self-identify as African-American, Black, or mixed race including African American or Black
- have been assigned male sex at birth
- self-identify as gay, bisexual, or queer, or self-identify as a heterosexual male who has had a past voluntary sexual experience with another man or currently has sexual desires for men
- report being uninfected with HIV
- be mentally capable of providing informed consent
- be able to speak and read English
- not currently using PrEP for HIV.
Exclusion Criteria:
- HIV-infected men are excluded because this study is focused on the prevention of HIV transmission
- Men who were not assigned male sex at birth are excluded from this study, because transgender men face very different and distinct issues with access to care compared to YMSM
- Men who are currently using PrEP are excluded from this study because this study is exploring the barriers and facilitators to use of PrEP in African American YMSM aged 16-24. Men who are currently using PrEP may have a different illness representation compared to men who are not using PrEP.
Study Plan
How is the study designed?
Design Details
- Observational Models: Ecologic or Community
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
African American YMSM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Factors that influence African American YMSM's likely use of PrEP
Time Frame: During patient interview, approximately 1.5 hours
|
During patient interview, approximately 1.5 hours
|
|
Cognitive processes in response to using PrEP to reduce risk for HIV
Time Frame: During patient interview, approximately 1.5 hours
|
During patient interview, approximately 1.5 hours
|
|
Emotional processes in response to using PrEP to reduce risk for HIV
Time Frame: During patient interview, approximately 1.5 hours
|
During patient interview, approximately 1.5 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Pro00070892
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
Duke UniversityGilead SciencesRecruitingHIV Prevention | HIV Pre-exposure Prophylaxis | HIV Prevention Program | HIV Prevention and Care | HIV Pre-exposure Prophylaxis UseUnited States
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecruitingPrEP | HIV | HIV Prevention | PrEP UptakeUnited States
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)RecruitingHIV Prevention | PrEP Adherence | HIV Related StigmaThailand
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingFeasibility | HIV Prevention | PrEP Uptake | Acceptability | HIV Self-testing | Male Partners of HIV-negative Postpartum WomenSouth Africa
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of PennsylvaniaNational Institute of Mental Health (NIMH); University of BotswanaRecruitingPregnancy | HIV | Post-partum | HIV Antiretroviral Therapy (ART) AdherenceBotswana
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
Instituto Mexicano del Seguro SocialRecruitingWeight Loss | HIV | HIV-1 Infection | Weight Change | HIV Associate Weight Loss | Integrase Inhibitors, HIV; HIV PROTEASE INHIBMexico
Clinical Trials on No intervention used
-
Lawson Health Research InstituteCompletedUveitis | Macular Edema | Retinal Vein Occlusion | Retinitis | Orbital Diseases | Optic Neuritis | Keratoconjunctivitis Sicca | Conjunctivitis | Blindness | Xerophthalmia | Papilledema | Iridocyclitis | Retinal Artery Occlusion | Amaurosis Fugax | Scleritis | Eye Hemorrhage | Chorioretinitis | Choroid Hemorrhage
-
ProgenaBiomeCompletedCovid19 | SARS-CoV2 Infection | COVID-19 Pneumonia | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | COVID-19 Acute Bronchitis | COVID-19 Lower Respiratory InfectionUnited States
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaCompletedObesity | Type2 DiabetesUnited States
-
Royal Brompton & Harefield NHS Foundation TrustCompletedNeuromuscular Diseases | Neurologic DisorderUnited Kingdom
-
Region SkaneLund UniversityRecruitingPersonality Disorders | Depression | Anhedonia | Suicide, Attempted | Psychiatric Diagnosis | CYP2D6 PolymorphismSweden
-
Muş Alparlan UniversityNot yet recruiting
-
Duke UniversityJohn Templeton FoundationTerminatedCannabis Use | Drug Use | Development, InfantUnited States
-
Erasmus Medical CenterNot yet recruiting
-
University of JordanCompletedInflammatory Bowel DiseasesJordan
-
Universiti Tunku Abdul RahmanCompletedUniversity StudentsMalaysia